FDA creates expanded access working group

FDA has created a working group to develop policies that would improve access to investigational therapies, Richard Moscicki, deputy director for science operations at the agency's Center for Drug Evaluation and Research, told BioCentury.

The agency's Office of the Commissioner will lead the working group. "The number one priority has been to simplify the procedure and forms for the application of individual INDs," Moscicki said. ...